Literature DB >> 12203417

Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.

Akira Otaka1, Miki Nakamura, Daisuke Nameki, Eiichi Kodama, Susumu Uchiyama, Syota Nakamura, Hiroaki Nakano, Hirokazu Tamamura, Yuji Kobayashi, Masao Matsuoka, Nobutaka Fujii.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12203417     DOI： 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


× No keyword cloud information.
  60 in total

1.  Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.

Authors:  Lifeng Cai; Chungen Pan; Liang Xu; Yuan Shui; Keliang Liu; Shibo Jiang
Journal:  FASEB J       Date:  2011-11-15       Impact factor: 5.191

2.  Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.

Authors:  Yang Su; Huihiui Chong; Shengwen Xiong; Yuanyuan Qiao; Zonglin Qiu; Yuxian He
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

3.  A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41.

Authors:  Miriam Gochin; Ryan Savage; Spencer Hinckley; Lifeng Cai
Journal:  Biol Chem       Date:  2006-04       Impact factor: 3.915

4.  Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.

Authors:  Daisuke Nameki; Eiichi Kodama; Mieko Ikeuchi; Naoto Mabuchi; Akira Otaka; Hirokazu Tamamura; Mutsuhito Ohno; Nobutaka Fujii; Masao Matsuoka
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway.

Authors:  Makoto Ujike; Hiroki Nishikawa; Akira Otaka; Naoki Yamamoto; Norio Yamamoto; Masao Matsuoka; Eiichi Kodama; Nobutaka Fujii; Fumihiro Taguchi
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

6.  Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.

Authors:  John J Dwyer; Karen L Wilson; Donna K Davison; Stephanie A Freel; Jennifer E Seedorff; Stephen A Wring; Nicolai A Tvermoes; Thomas J Matthews; Michael L Greenberg; Mary K Delmedico
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-19       Impact factor: 11.205

7.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.

Authors:  Paolo Ingallinella; Elisabetta Bianchi; Neal A Ladwa; Ying-Jie Wang; Renee Hrin; Maria Veneziano; Fabio Bonelli; Thomas J Ketas; John P Moore; Michael D Miller; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

8.  A suite of modular fluorescence assays interrogate the human immunodeficiency virus glycoprotein-41 coiled coil and assist in determining binding mechanism of low molecular weight fusion inhibitors.

Authors:  Miriam Gochin
Journal:  Assay Drug Dev Technol       Date:  2012-08-16       Impact factor: 1.738

9.  Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.

Authors:  Kazuki Izumi; Eiichi Kodama; Kazuya Shimura; Yasuko Sakagami; Kentaro Watanabe; Saori Ito; Tsuyoshi Watabe; Yukihiro Terakawa; Hiroki Nishikawa; Stefan G Sarafianos; Kazuo Kitaura; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

10.  Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors.

Authors:  Zhi Qi; Weiguo Shi; Na Xue; Chungen Pan; Weiguo Jing; Keliang Liu; Shibo Jiang
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.